Based on the Allovir Inc stock forecast from 0 analysts, the average analyst target price for Allovir Inc is not available over the next 12 months. Allovir Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allovir Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Allovir Inc’s stock price was USD 0.45. Allovir Inc’s stock price has changed by -4.88% over the past week, -15.30% over the past month and -34.59% over the last year.
No recent analyst target price found for Allovir Inc
No recent average analyst rating found for Allovir Inc
Company Overview Allovir Inc
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Read Less
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogene...Read More
Frequently Asked Questions About Allovir Inc (ALVR) Stock
Stock Target Advisor's fundamental analysis for Allovir Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ALVR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ALVR's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ALVR's stock to indicate if its overvalued.
The last closing price of ALVR's stock was USD 0.45.
The most recent market capitalization for ALVR is USD 0.09B.
Unfortunately we do not have enough analyst data on ALVR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Allovir Inc's stock.
As per our most recent records Allovir Inc has 8 Employees.
Allovir Inc's registered address is 1100 Winter Street, Waltham, MA, United States, 02451.
You can get more information about it from Allovir Inc's website at https://www.allovir.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Allovir Inc (ALVR) Stock
Stock Target Advisor's fundamental analysis for Allovir Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ALVR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ALVR's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ALVR's stock to indicate if its overvalued.
The last closing price of ALVR's stock was USD 0.45.
The most recent market capitalization for ALVR is USD 0.09B.
Unfortunately we do not have enough analyst data on ALVR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Allovir Inc's stock.
As per our most recent records Allovir Inc has 8 Employees.
Allovir Inc's registered address is 1100 Winter Street, Waltham, MA, United States, 02451.
You can get more information about it from Allovir Inc's website at https://www.allovir.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALVR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
